Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18 participants
OBSERVATIONAL
2013-04-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PK and PD of Antibiotics for Treatment of Mycobacterium Abscessus Pulmonary Disease
NCT05676138
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
NCT00987792
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
NCT00887276
Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas
NCT00538018
Pharmacokinetics of Levofloxacin in Intensive Care Unit
NCT02018081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pharmacokinetics Moxifloxacin
Patients with community-acquired pneumonia treated with moxifloxacin
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kristina Öbrink-Hansen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eskild Petersen, MD, Assoc. Prof., D.Sc.
Role: STUDY_DIRECTOR
Department of Infectious Diseases, Aarhus University Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Infectious Diseases, Aarhus University Hospital
Aarhus, Aarhus N, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Obrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 2015 Apr;59(4):2398-404. doi: 10.1128/AAC.04659-14. Epub 2015 Feb 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-58-0010
Identifier Type: OTHER
Identifier Source: secondary_id
MOXI-274-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.